QED Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
75 Federal St, San Francisco, California...Phone Number
(650) 231-4088Website
www.qedtx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About QED Therapeutics
QED Therapeutics specializes in developing treatments for skeletal dysplasias, including achondroplasia and hypochondroplasia. The company is dedicated to research and has been involved in clinical trials, such as the breakthrough therapy designation by the FDA for its investigational drug infigratinib. Their target clients include healthcare professionals and individuals affected by these conditions, providing resources and advocacy support. As an affiliate of BridgeBio, QED Therapeutics aims to enhance the quality of life for those with skeletal dysplasias through innovative therapies and community engagement.Explore more
QED Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is QED Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when QED Therapeutics launches new products
Click to see if QED Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once QED Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at QED Therapeutics
Earning: See what the market has to say on QED Therapeutics recently announced quarterly report
QED Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if QED Therapeutics is spiking on competitors!
Check if QED Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to QED Therapeutics
Compare insights from companies similar to QED Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
QED Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
QED Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about QED Therapeutics.
QED Therapeutics Tech Stack
A closer look at the technologies used by QED Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
QED Therapeutics News & Media
BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated advanced cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangementBridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology
- BridgeBio, through its affiliate QED (“BridgeBio”), and Helsinn to co-commercialize infigratinib for oncology and all other indications other than skeletal dysplasia indications in the U.S. and equally share profitsBridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma
• Application accepted under Priority Review designation • Application accepted into Real Time Oncology Review (RTOR) pilot program • This is BridgeBio’s second NDA acceptance • Application will also be submitted for review in Australia and Canada under Project OrbisBridgeBio Pharma Expands Reach Into China and Other Major Asian Markets Through Strategic Collaboration With Perceptive Advisors-Founded Company, LianBio
$26.5 million total near-term payments to BridgeBio, plus participation in long-term value creation of up to $505 million in milestone payments, tiered double-digit royalty payments and an equity interest in LianBio.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding QED Therapeutics
Sign Up For FreeTo access detailed company insights
QED Therapeutics specializes in developing treatments for skeletal dysplasias, including achondroplasia and hypochondroplasia. The company is dedicated to research and has been involved in clinical trials, such as the breakthrough therapy designation by the FDA for its investigational drug infigratinib. Their target clients include healthcare profe... Read More
